European Commission Approves Pembrolizumab in MSI-H/dMMR Solid Tumors

Article

Pembrolizumab has been approved by the European Commission in 5 indications of solid tumors that are microsatellite instability–high or deficient mismatch repair.

Pembrolizumab (Keytruda) has been approved by the European Commission for patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) tumors, according to a press release from Merck.

The approval is based on results from the phase 2 KEYNOTE-164 trial (NCT02460198)— assessing the monotherapy in patients with previously treated locally advanced unresectable of metastatic colorectal cancer—and the phase 2 KEYNOTE-158 trial (NCT02628067)—examining pembrolizumab in advanced solid tumors.

Patients with colorectal cancer (n = 124) had an objective response rate (ORR) of 34.0% (95% CI, 25.6%-42.9%) with a complete response (CR) rate of 10.0% after a median follow-up of 37.3 months. After a median follow-up of 21.9 years, those with endometrial cancer (n = 83) had an ORR of 51.0% (95% CI, 39.4%-61.8%), a CR rate of 16.0%. Those with gastric cancer (n = 51) had an ORR of 37.0% (95% CI, 24.1%-51.9%), with a CR rate of 14.0% after a median follow-up of 13.9 months. Those with small intestine cancer (n = 27) had an ORR of 56.0% (95% CI, 35.3%-74.5%), with a CR rate of 15.0% and a median follow-up of 29.1 months. Those with biliary cancer (n = 22) had an ORR of 41.0% (95% CI, 20.7%-63.6%), with a CR rate of 14.0%, and a median follow-up of 19.4 months.

“The [European Commission] approval of [pembrolizumab] is an important milestone for patients living with these MSI-H/dMMR cancers who have had few treatment options and face worse outcomes when diagnosed at an advanced stage,” Aurélien Marabelle, MD, PhD, immuno-oncologist at Gustave Roussy Cancer Center and Professor of Clinical Immunology at the University of Paris Saclay, said in the press release.

Reference

European Commission approved Merck’s Keytruda (pembrolizumab) for patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in five different types of cancer. News Release. Merck. April 29, 2022. Accessed May 6, 2022. https://bit.ly/3waOTJz

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.

Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer

April 23rd 2024
Article

A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors

April 8th 2024
Article

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.

China Accepts sNDA for Savolitinib in Previously Treated MET Exon 14 NSCLC

April 6th 2024
Article

Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.